恶性骨肿瘤患者血清中肿瘤坏死因子-β和可溶性肿瘤坏死因子受体水平
Serum levels of TNF-beta and sTNF-R in patients with malignant bone tumours.
作者信息
Holzer G, Pfandlsteiner T, Blahovec H, Trieb K, Kotz R
机构信息
Department of Orthopaedics, University of Vienna, Vienna General Hospital, Währinger Gürtel 18-20, A-1090 Vienna, Austria.
出版信息
Anticancer Res. 2003 May-Jun;23(3C):3057-9.
OBJECTIVE
To determine serum levels of TNF-beta and soluble TNF-R in patients with primary highly malignant bone tumours.
PATIENTS AND METHODS
Sera of 27 patients with highly malignant osteosarcoma and Ewing sarcoma were taken at the time of diagnosis and analysed by ELISA.
RESULTS
Both TNF-beta and sTNF-R levels were lower in sera from osteosarcoma patients as compared to those from Ewing sarcoma. In patients with high-grade osteosarcoma, but not Ewing sarcoma, high levels of TNF-beta correlated with bad response to neoadjuvant chemotherapy.
CONCLUSION
In patients with high-grade osteosarcoma TNF-beta levels seem to be of predictive value and both TNF-beta and sTNF-R seem to be of diagnostic value for differentiation between high-grade osteosarcoma and Ewing sarcoma.
目的
测定原发性高度恶性骨肿瘤患者血清中肿瘤坏死因子-β（TNF-β）和可溶性肿瘤坏死因子受体（sTNF-R）水平。
患者与方法
收集27例高度恶性骨肉瘤和尤因肉瘤患者诊断时的血清，采用酶联免疫吸附测定（ELISA）法进行分析。
结果
骨肉瘤患者血清中的TNF-β和sTNF-R水平均低于尤因肉瘤患者。在高级别骨肉瘤患者中，而非尤因肉瘤患者中，高水平的TNF-β与新辅助化疗反应不佳相关。
结论
在高级别骨肉瘤患者中，TNF-β水平似乎具有预测价值，且TNF-β和sTNF-R对于高级别骨肉瘤与尤因肉瘤的鉴别诊断似乎均具有诊断价值。
Zotero 插件